Harvard Bioscience (HBIO) Stock Price, News & Analysis

Company Overview

Harvard Bioscience, Inc. develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools. The company serves its customers via direct sales and an extensive distributor network, with significant operations in North America, Europe and the Asia‐Pacific region.

Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has grown through organic innovation and strategic acquisitions to support the evolving needs of life science research. The company maintains manufacturing and R&D facilities in the United States and Europe and is managed by an experienced team of professionals with backgrounds in engineering, sales and scientific product development.

Key Stats

• Today's Range: $5.27 to $5.59
• 50-Day Range: $4.31 to $7.24
• 52-Week Range: $2.81 to $9.50
• Volume: 22,708 shs
• Average Volume: 40,571 shs
• Market Capitalization: $24.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Harvard Bioscience Stock Analysis - MarketRank™

Harvard Bioscience scored higher than 56% of companies evaluated by MarketBeat, and ranked 399th out of 632 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Harvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Harvard Bioscience is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Harvard Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harvard Bioscience is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harvard Bioscience is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harvard Bioscience has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.75% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 4.14.

Change versus previous month

Short interest in Harvard Bioscience has recently decreased by 29.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harvard Bioscience does not currently pay a dividend.

Dividend Growth

Harvard Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.73

News Sentiment

Harvard Bioscience has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Harvard Bioscience this week, compared to 6 articles on an average week.

MarketBeat Follows

1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Harvard Bioscience in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $177,354.00 in company stock, which represents 0.7124% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Harvard Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $177,354.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

20.30% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/15/2026
• Sidoti Micro-Cap Virtual Conference: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: INSTRU - SCIENTFC
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:HBIO
• CIK: 1123494
• Web: www.harvardbioscience.com
• Phone: (508) 893-8999
• Fax: 508-429-5732
• Employees: 490
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Harvard Bioscience: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +8.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.70 million
• Net Margins: -11.44%
• Pretax Margin: -11.57%
• Return on Equity: -25.78%
• Return on Assets: -4.37%

Debt

• Debt-to-Equity Ratio: 3.60
• Current Ratio: 1.99
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: $86.55 million
• Price / Sales: 0.29
• Cash Flow: $11.50 per share
• Price / Cash Flow: 0.48
• Book Value: $2.23 per share
• Price / Book: 2.48

Miscellaneous

• Outstanding Shares: 4,510,000
• Free Float: 3,594,000
• Market Cap: $24.90 million
• Optionable: Optionable
• Beta: 1.57